Cargando…
Managed Care Perspective on Three New Agents for Type 2 Diabetes
BACKGROUND: Despite effective monotherapy for diabetes, approximately 50% of patients require additional medications after 3 years to achieve target glycosylated hemoglobin (A1C) less than 7%. Three new agents, each the first in its therapeutic class with a unique mechanism of action, have been appr...
Autores principales: | VanDeKoppel, Shawna, Choe, Hae Mi, Sweet, Burgunda V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438140/ https://www.ncbi.nlm.nih.gov/pubmed/18500914 http://dx.doi.org/10.18553/jmcp.2008.14.4.363 |
Ejemplares similares
-
Formulary Management of 2 New Agents: Lorcaserin and Phentermine/Topiramate for Weight Loss
por: Kelly, Elizabeth M., et al.
Publicado: (2013) -
Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis
por: Schafer, Jeremy A., et al.
Publicado: (2010) -
Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents
por: Campbell, Helen Eloise
Publicado: (2005) -
A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults
por: Payakachat, Nalin, et al.
Publicado: (2006) -
Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis
por: Fisher, Vicki S.
Publicado: (2005)